ERVW-1 and infection: Data from in vitro studies show that HIV-1 Env-specific mucosal IgA can block HIV entry and transcytosis, [25–28] and even low level nAb titres can be sufficient to reduce infection by repeated low-dose challenge [29], thus induction of antigen-specific IgA in the vagina may be a desirable outcome for an HIV vaccine.